Latest Breaking News On - Overall efficacy - Page 1 : comparemela.com

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial Reportable 15 Jun 2021, 01:16 GMT+10 Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial GAITHERSBURG, Md., June 14, 2021 - Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. The study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.

South africaLaura keenanErika schultzAlison chartanExchange commissionReportable incNovavax incOverall efficacyProtection against moderateSevere diseaseNovavax annual reportலாரா கீநெந்எரிகா ஶுல்ட்ஸ்பரிமாற்றம் தரகுகடுமையானது நோய்